Save time and get answers to complex questions with AI chat
Complera manufacturer?Bivalirudin manufacturer?Combivent inhaler hfc 152a patents?Is guselkumab off patent in u s?Drug patent watch trametinib?
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses the immune system. Novartis, the manufacturer, recommends completing all age-appropriate immunizations before starting Cosentyx. Live vaccines should be avoided during treatment and for at least 4-6 weeks after the last dose due to infection risk.[1]
No major safety issues reported with inactivated vaccines, but efficacy drops 20-50% for some (e.g., flu, pneumococcal). Live vaccines risk disseminated infection, though rare cases exist. Monitor for poor response via titer checks if high-risk.[3][5]
Consult your rheumatologist or dermatologist—they may test immunity levels or adjust timing based on disease activity. CDC and ACR guidelines align: prioritize pre-treatment vaccination, favor non-live options.[2][6] No head-to-head trials compare pre- vs. post-dosing efficacy directly. Sources [1] Cosentyx Prescribing Information (Novartis) [2] CDC Vaccine Guidelines for Immunocompromised Adults [3] ACR Guidelines on Vaccinations in Rheumatic Diseases [4] Study on COVID-19 Vaccine Response in IL-17 Inhibitors (JAMA Dermatology, 2022) [5] EMA Cosentyx Summary of Product Characteristics [6] UpToDate: Vaccinations in Patients on Biologics
Other Questions About Vaccines :